Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03457922 · ClinicalTrials.gov registry record

Evaluating a Personalized Trans-Diagnostic Group Therapy for Anxiety

A clinical trial of Anxiety Disorders, sponsored by Stanford University.

Completed
Registry status
45
Enrollment target
1
Study location

NCT03457922: Completed study of Anxiety Disorders, sponsored by Stanford University.

NCT03457922 is a study of Anxiety Disorders that has completed, run by Stanford University. The registered enrollment target is 45 participants, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03457922, a study of Anxiety Disorders, has completed, sponsored by Stanford University.

COMPLETED
Registry status
45 participants
Enrollment target
1
Study location

Study Summary

This study is examining the impact of a therapy group for all anxiety disorders provided by the Stanford Department of Psychiatry and Behavioral Sciences's Psychosocial Treatment Clinic on anxiety symptoms, impairment, and access to quality mental health care.

Primary Outcome

Measures overall anxiety severity and anxiety-related impairment due to any anxiety disorder. Total scores are computed by summing scores from all 5 items. Total score ranges from 0 to 20, with higher scores indicating higher severity and impairment of anxiety symptoms. Reduction in OASIS scores therefore indicates better outcome.

Conditions Studied

Study Locations (1)

California

  • Stanford University Department of Psychiatry & Behavioral Sciences - Palo Alto

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2018-02-05
Est. Completion 2019-10-06
Stanford University

1,744 total trials

What the finished NCT03457922 record still lists

NCT03457922 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Anxiety Disorders appearing as the primary indexed condition, and to 0 interventions.

NCT03457922 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03457922 about?

NCT03457922 is a clinical study titled "Evaluating a Personalized Trans-Diagnostic Group Therapy for Anxiety". This study is examining the impact of a therapy group for all anxiety disorders provided by the Stanford Department of Psychiatry and Behavioral Sciences's Psychosocial Treatment Clinic on anxiety symptoms, impairment, and access to quality mental health care.

What is the current status of trial NCT03457922?

This trial is currently completed. The enrollment target is 45 participants. The study started on 2018-02-05. Estimated completion is 2019-10-06.

What conditions does trial NCT03457922 study?

This clinical trial studies the following conditions: Anxiety Disorders.

Who is sponsoring clinical trial NCT03457922?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03457922 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03457922's enrollment target sits among peer trials

45 69th of 84 higher than 15 of 84 other Anxiety Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03457922, the US trial registry maintained by the National Library of Medicine. NCT03457922 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.